Related Experiment Videos
[Therapy with an antibiotic combination mezlocillin/oxacillin and clinical experience/Second communication: Children
Insights
Optocillin, a mezlocillin and oxacillin combination, effectively treated bacterial infections in 90% of pediatric patients, including newborns and premature infants. This antibiotic combination demonstrated excellent tolerance during long-term use.
Area of Science:
- Pediatric Infectious Diseases
- Bacterial Infections in Neonates
- Antibiotic Therapy Efficacy
Context:
- Neonatal infections require prompt antibiotic treatment due to diagnostic challenges and critical patient conditions.
- A multicenter study assessed therapeutic outcomes in 51 children with bacterial infections.
- 17% of patients were neonates, and 12 were premature infants, some with significant immaturity.
Purpose:
- To evaluate the therapeutic efficacy and tolerance of Optocillin (mezlocillin and oxacillin combination) in pediatric bacterial infections.
- To determine optimal dosage and long-term treatment effectiveness in vulnerable infant populations.
Summary:
- Optocillin treatment resulted in a 90% effectiveness rate in pediatric patients with bacterial infections.
- The study included 51 children, with a significant proportion being neonates and premature infants.
- An average daily dose of 225 mg/kg was effective and well-tolerated, even in prolonged treatments for neonatal septicemia.
Impact:
- Optocillin offers a highly effective and well-tolerated treatment option for bacterial infections in neonates and children.
- Demonstrates the safety and efficacy of combined antibiotic therapy in critically ill infants.
- Supports the use of prompt antibiotic intervention in suspected neonatal infections.
Abstract:
Almost all infections of newborn have to be treated with antibiotics before the result of microbiological examination is available since there are either difficulties in identifying the causative organisms(s) or antibiotic treatment must be instituted without delay in view of the patient's life threatening condition. The present paper reports on the therapeutic results obtained in association with the multicentre study of 51 children affected by bacterial infections. 17 (33.0%) patients were newborn up to one week of age. 12 patients were classified as premature babies, some presenting a high degree of immaturity. Treatment with Optocillin (Bay 1-1330), a combination of 6-((R)-2-[3-Methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido)-penicillanic acid sodium salt (mezlocillin, Baypen) and 5-methyl-3-phenyl-4-isoxazolyl-penicillin (oxacillin, Stapenor), proved effective in 90% of the children, although 22 patients had been treated with other antibiotics prior to the use of this compound. An average daily dose of about 225 mg/kg bodyweight was found to be effective and perfectly tolerated even on long-term treatment, as became evident from two cases of extremely premature babies effected by neonatal septicaemia (duration of treatment 38 and 34 days, respectively). The combination showed a perfect local tolerance, exanthema appearing only in one infant.